Contrasting of DiaMedica Therapeutics Inc. (DMAC) and Its Rivals

As Biotechnology company, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is competing with its rivals based on the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Institutional and Insider Ownership

DiaMedica Therapeutics Inc. has 13.72% of its shares owned by institutional investors & an average of 53.20% institutional ownership for its rivals. 8.37% of DiaMedica Therapeutics Inc. shares are owned by company insiders. Comparatively, 8.45% of all Biotechnology companies shares are owned by company insiders.

Profitability

Table 1 has DiaMedica Therapeutics Inc. and its competitors’ return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
DiaMedica Therapeutics Inc. 297,951,582.87% 0.00% 0.00%
Industry Average 812.10% 105.95% 28.39%

Valuation and Earnings

In next table we are comparing DiaMedica Therapeutics Inc. and its competitors’ gross revenue, valuation and net income.

Net Income Gross Revenue Price/Earnings Ratio
DiaMedica Therapeutics Inc. 9.12M 3 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Recommendations

Table 3 shows breakdown of recent ratings for DiaMedica Therapeutics Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
DiaMedica Therapeutics Inc. 0 0 1 3.00
Industry Average 1.10 1.78 2.38 2.81

$11 is the consensus price target of DiaMedica Therapeutics Inc., with a potential upside of 290.07%. The rivals have a potential upside of 168.19%. Based on the data given earlier, DiaMedica Therapeutics Inc.’s rivals are looking more favorable than the company itself, research analysts’ view.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of DiaMedica Therapeutics Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
DiaMedica Therapeutics Inc. -0.53% -23.25% 11.93% -2.51% -54.51% 28.18%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year DiaMedica Therapeutics Inc. was less bullish than its rivals.

Dividends

DiaMedica Therapeutics Inc. does not pay a dividend.

Summary

DiaMedica Therapeutics Inc.’s rivals beat DiaMedica Therapeutics Inc. on 3 of the 4 factors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.